mutations

Malignant pleural mesothelioma is rare and often has a poor outlook in cancer treatment. Immunotherapy, especially immune checkpoint inhibitors, has brought hope. It shows potential for better outcomes in mesothelioma patients. A new article in Open Respiratory Archives provides a history of recent advances in immunotherapy for malignant pleural mesothelioma patients. Understanding Malignant Pleural Mesothelioma Mesothelioma starts in pleural cavity cells and comes from asbestos exposure. It has three types: epithelioid, sarcomatoid, or biphasic. They show its diversity and complexity. Treatments may use the immune system or genetic information to help boost effectiveness. Immunotherapies are used to treat mesothelioma cancer. Immunotherapy is also referred to as biological therapy, and utilizes the patient’s immune system to treat mesothelioma. These treatments typically…